Resmedica Sp. z o.o.

Resmedica Sp. z o.o. conducts research on multiple sclerosis, an immune‑mediated condition affecting the central nervous system, aiming to test new immunotherapies and improve patient outcomes.

• Relapsing‑remitting multiple sclerosis
• Anti‑CD20 monoclonal antibody approaches
• Novel oral agents targeting immune pathways
• Pharmacokinetic and safety assessments in lactating women
• Patient‑reported outcome measures

The site hosts 12 clinical trials led by 9 investigators in Kielce, Poland, focusing on efficacy, safety, and disease activity measured by MRI.

Studies address the progressive forms of multiple sclerosis, seeking therapies that slow neurodegeneration and reduce disability.

• Primary progressive multiple sclerosis
• Secondary progressive multiple sclerosis
• Brain atrophy measured by quantitative MRI
• Disability progression endpoints such as EDSS and 9‑HPT
• Add‑on treatments combined with ocrelizumab

Across the 12 trials, investigators evaluate long‑term safety and the impact on brain atrophy and functional decline, supporting advances in neurological care.